Person:
OYSU, ÇAĞATAY

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

OYSU

First Name

ÇAĞATAY

Name

Filters

20223
Reset filters

Settings

Author: YUMUŞAKHUYLU, ALİ CEMAL × Subject: Clinical Medicine (MED) ×

Search Results

Now showing 1 - 3 of 3
  • No Thumbnail Available
    PublicationMetadata only
    Diagnostic Features and Risk Factors for Childhood Thyroid Cancers
    (2022-09-01) ŞAHİN, PINAR; GÜRPINAR TOSUN, BUŞRA; YUMUŞAKHUYLU, ALİ CEMAL; GÜRAN, TÜLAY; HALİLOĞLU, BELMA; OYSU, ÇAĞATAY; DEMİRCİOĞLU, SERAP; BEREKET, ABDULLAH; ŞAHİN P., GÜRPINAR TOSUN B., YUMUŞAKHUYLU A. C. , GÜRAN T., Helvacioglu D., Abali Z. Y. , HALİLOĞLU B., OYSU Ç., BEREKET A., DEMİRCİOĞLU S.
  • Thumbnail Image
    PublicationOpen Access
    Relationship of PPARG overexpression with prognostic parameters in papillary thyroid carcinoma
    (2022-02-01) ASYA, ORHAN; YUMUŞAKHUYLU, ALİ CEMAL; BAĞCI ÇULÇİ, PELİN; ŞAHİN, AKIN; OYSU, ÇAĞATAY; KAYA, HANDAN; ASYA O., YUMUŞAKHUYLU A. C., BAĞCI ÇULÇİ P., KAYA H., Gonen A., Gundogdu Y., Muradov T., ŞAHİN A., OYSU Ç.
    Objectives. PAX8/PPARG chromosomal rearrangement is frequently seen in thyroid cancer, and PPARG overexpression has been shown in the follicular variant of papillary thyroid carcinoma, but not in papillary thyroid carcinoma other than the follicular variant. The main aim of this study was to investigate the frequency of PPARG overexpression among papillary thyroid carcinoma and if there were any variants of papillary thyroid carcinoma with PPARG overexpression other than the follicular variant. Methods. Immunohistochemical analysis of PPARG overexpression was performed using a PPARG monoclonal antibody in a series of 111 paraffin-embedded blocks of thyroid tumours. Of the patients in our study, 100 were diagnosed with papillary thyroid carcinoma, 9 with follicular adenoma and 2 with follicular carcinoma. Results. PPARG staining was detected in 19 of the 111 cases. Sixteen patients with PPARG overexpression had papillary thyroid carcinoma and 3 had follicular adenoma. Conclusion. PPARG overexpression was detected mainly in follicular-variant papillary thyroid carcinoma. Vascular invasion, lymphatic invasion, thyroid capsule invasion and lymph node positivity were lower in patients with PPARG overexpression.
  • Thumbnail Image
    PublicationOpen Access
    A single-center multidisciplinary study analyzing thyroid nodule risk stratification by comparing the thyroid imaging reporting and data system (TI-RADS) and American thyroid association (ATA) risk of malignancy for thyroid nodules
    (2022-01-01) ASYA, ORHAN; YUMUŞAKHUYLU, ALİ CEMAL; ENVER, NECATİ; İNCAZ, SEFA; GÜNDOĞMUŞ, CEMAL AYDIN; ERGELEN, RABİA; BAĞCI ÇULÇİ, PELİN; OYSU, ÇAĞATAY; ASYA O., YUMUŞAKHUYLU A. C. , ENVER N., Gündoğdu Y., Abuzaid G., İNCAZ S., GÜNDOĞMUŞ C. A. , ERGELEN R., Bağcı P., OYSU Ç.
    © 2022 Elsevier LtdObjectives: The thyroid imaging reporting and data system (TI-RADS) and 2015 American Thyroid Association (ATA) guidelines are two well-known risk stratification systems for classifying thyroid nodules based on cancer risk. This study aims to evaluate the diagnostic efficacy of these two systems in predicting malignancy in patients undergoing thyroid surgery. Methods: We studied data on 120 individuals who were scheduled to undergo surgery for benign or malignant nodular diseases of the thyroid gland between October 2017 and October 2019. The TI-RADS category and ultrasound pattern based on ATA guidelines were assigned to dominant thyroid nodule categories by two experienced radiologists blinded to patients’ previous thyroid ultrasonography and fine-needle aspiration biopsy results. A pathologist with experience in thyroid diseases blinded to patients’ sonographic and clinical data reviewed the thyroidectomy specimens. Results: A total of 120 patients, 88 women and 32 men, were included in our study. Final histopathological results were as follows: 50% (n=60) papillary thyroid carcinoma, 36.6% (n=44) benign nodular thyroid diseases, 4.1% (n=5) follicular adenoma, 2.5% (n=3) hurtle cell adenoma, 1.7% (n=2) follicular thyroid carcinoma, 1.7% (n=2) medullary thyroid carcinoma, 1.7% (n=2) hurtle cell carcinoma, and 1.7% (n=2) follicular tumor of uncertain malignancy potential. The sensitivity, specificity, positive predictive value, and negative predictive value for TI-RADS were 80%, 56%, 72%, and 67%, respectively, and that for ATA were 80%, 64%, 76%, and 69%, respectively. Conclusion: The TI-RADS and ATA showed similar rates of sensitivity, specificity, NPV, and PPV. Our observed risk of malignancy was higher than expected for the ACR TI-RADS 3–5 categories and the very low, low, and intermediate suspicion risk strata in the ATA guidelines. We found no difference between observed and expected malignancy risk for the ACR TI-RADS 2’s and ATA\"s high suspicion categories.